Mythologizing the Story of a Scientific Invention: Constructing the legitimacy of research commercialization

This paper explores the processes through which an organizational story acquires mythological status within an organizational field. To this end, I analyse a story of a successful case of academic technology transfer that gained mythological status in the field of higher education in Israel: the commercialization of the innovative pharmaceutical drug Copaxone. I identify three concurrent processes of mythologizing work: organizational storytelling, media diffusion and reconstruction, and field-level retelling and countering. I argue that myth-making is a collective work, in which an organizational story is shaped not only through the strategic rhetorical work of managers but also through interpretations and modifications by the media as well as other actors in the field. The myth of Copaxone, as it is currently told in the field of higher education in Israel, is a complex assemblage of the organizational story and various counter-narratives. I further suggest that this myth not only serves to naturalize and reinforce academic patenting, but also constitutes a discursive space for reflections about the ambiguities inherent in academic commercialization.

Academic patenting in Brazil: the role of academic inventors in PCT patent applications – 2002-2012

Purpose The purpose of this paper is to analyse the patenting activity of the Brazilian academic sector vis-à-vis the domestic business sector, taking into account the recent evolution of Brazil’s industrial policies. The paper differentiates between “university academic patents”, which are owned by the universities, and “non-university academic patents”, which despite being invented by academic staff are not owned by the universities. Design/methodology/approach The authors’ cross-checked information regarding the names of all inventors with Brazilian addresses in PCT patent applications in the Espacenet database with the names of researchers in the CVs available on the Lattes Platform of CNPq. The analysis specifically focussed on patent applications published in the PCT with Brazilian priority for the 2002-2012 period. Findings It was found that the Brazilian academic patents concentrate on science-based technology areas, especially in the Pharma Biotechnology domain. For a total of 466 patent applications with Brazilian priority in this field, 233 have academic inventors. Of those 233 academic applications, 66.1 per cent have universities as their owners, while the remaining 33.9 per cent are not owned by universities. Further, it was found that there are more Brazilian academic patents in the biotechnology sub-domain than those filed by the business sector. Research limitations/implications This research was based on the intersection of patent databases and the content available on the official curriculum base of Brazil (Lattes Platform, CNPq). Once the curricula information are voluntary, there are risks inherent reliability of this information. Practical implications This study allows us to identify more accurately which is the effective role of the Brazilian Academy in patents generation, revealing that a significant unaccounted deposits with personal inventors or companies’ ownership really have a academic contribution. Originality/value This paper shows that the academic sector plays a key role in Brazil’s international patenting activity, particularly in science-intensive technology domains, and it highlights the specific contribution of academic patents not owned by universities.

From academic laboratory to the market: Disclosed and undisclosed narratives of commercialization

This paper examines how the Weizmann Institute of Science has been telling the story of the successful commercialization of a scientific invention, through its corporate communication channels, from the early 1970s to today. The paper aims to shed light on the transformation processes by which intellectual-property-based commercialization activities have become widely institutionalized in universities all over the world, and on the complexities, ambiguities and tensions surrounding this transition. We look at the story of the scientific invention of Copolymer-1 at the Weizmann Institute of Science and its licensing to Teva Pharmaceutical Industries, which subsequently developed the highly successful drug Copaxone for the treatment of multiple sclerosis. We argue that, in its tellings and retellings of the story of Copolymer-1, the Weizmann Institute has created narratives that serve to legitimize the institution of academic patenting in Israel.